RxPG News Feed for RxPG News

Medical Research Health Special Topics World
 Asian Health
 Food & Nutrition
 Men's Health
 Mental Health
 Occupational Health
 Public Health
 Sleep Hygiene
 Women's Health
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 World Healthcare
   Latest Research
 Alternative Medicine
 Clinical Trials
 Infectious Diseases
 Sports Medicine
   Medical News
 Awards & Prizes
   Special Topics
 Odd Medical News

Last Updated: Oct 11, 2012 - 10:22:56 PM
Orthopedics Channel

subscribe to Orthopedics newsletter
Latest Research : Orthopedics

   EMAIL   |   PRINT
TOPAZ(TM) Brings New Hope for Tennis Elbow

Jul 27, 2005 - 1:54:00 PM
"Our findings from the study demonstrate this procedure is technically simple to perform and is associated with a rapid and uncomplicated recovery. Treatment utilizing the TOPAZ MicroDebrider offers a new, minimally invasive alternative for millions of patients for whom conservative therapies have failed."

[RxPG] New study data published this month in Arthroscopy: The Journal of Arthroscopic & Related Surgery showed the use of a Coblation-based technology known as TOPAZ -- developed by ArthroCare(R) Corp. (Nasdaq:ARTC) -- to be effective when used in the treatment of common tendon disorders such as lateral epicondylitis, the condition commonly known as tennis elbow.

"Our findings from the study demonstrate this procedure is technically simple to perform and is associated with a rapid and uncomplicated recovery," said James P. Tasto, M.D. of San Diego Sports Medicine and Orthopedic Center, one of the study's authors and Professor of Orthopedic Surgery at the University of California, San Diego. "All participating patients showed significant improvement. Based upon the results of this study, the use of TOPAZ in the treatment of tendons is safe and effective for at least two years, post-op. Treatment utilizing the TOPAZ MicroDebrider offers a new, minimally invasive alternative for millions of patients for whom conservative therapies have failed."

The study, titled "Microtenotomy Using a Radiofrequency Probe to Treat Lateral Epicondylitis," consisted of thirteen subjects who had been suffering symptoms for six months or longer. Each of the patients had failed to achieve relief after conservative treatment. After treatment in which TOPAZ was used, the patients reported significant improvement only seven to 10 days after the procedures. In fact, 10 of the 13 subjects reported noticeable improvement only one or two days after the procedure.

"It's extremely gratifying when a study concerning one of our technology applications reveals such dramatically positive results," said Jack Giroux, ArthroCare Sports Medicine's President. "This is especially the case when the device in question, the TOPAZ MicroDebrider, has the opportunity to help such a large population -- those suffering from tendon conditions. While this particular study focused on the most common tendon-related complaint by patients seeking medical attention, TOPAZ is designed to be used to treat most tendons throughout the body."

The TOPAZ MicroDebrider is a wand-like device about the diameter of a pencil tip. Through a small incision, generally an inch in length, the physician applies the device to the problem tendon for multiple 500 millisecond intervals of treatment. By combining low temperature radiofrequency energy with saline, a charged plasma gas is formed at the tip of the TOPAZ wand and is precisely directed into and through the damaged tissues. From start to finish, the whole process takes less than 20 minutes.

"It should be noted," Tasto said, "that over the same period of time that the data was collected for this study, patients with other tendon conditions in the elbow, knee or shoulder were also treated using the TOPAZ wand -- and yielded similar results. I see great promise for this technology in an array of applications."

Publication: The study data is published this month in Arthroscopy: The Journal of Arthroscopic & Related Surgery
On the web: www.TOPAZinfo.com 

Advertise in this space for $10 per month. Contact us today.

Related Orthopedics News
Virtual models of human knee joints to study joints at tissue and cellular level
Delayed treatment of anterior cruciate ligament injuries lead to higher rates of other knee injury
Epidural steroid injections- an efficient treatment option for lumbar disc herniations
Gene in measles virus plays a key role in Paget's disease of bone
Ultrasound device speeds up broken bone healing
Programme reduces hip fractures by 37 percent
Drink tea for stronger bones, suggests study
Second SPORT Study Shows Surgery Advantage for Spinal Stenosis and Slipped Vertebra
Molecule that destroys bone also protects it, new research shows
Annual treatment with Zoledronic acid significantly reduces bone fractures

Subscribe to Orthopedics Newsletter

Enter your email address:

 Additional information about the news article
TOPAZ technology is now available in a quickly growing number of operating rooms around the country. To learn more about the procedure, visit www.TOPAZinfo.com.

About ArthroCare

Founded in 1993, ArthroCare Corp. (www.arthrocare.com) is a highly innovative, multi-business medical device company that develops, manufactures and markets minimally invasive surgical products. With these products, ArthroCare targets a multi-billion dollar market opportunity across several medical specialties, significantly improving existing surgical procedures and enabling new, minimally invasive procedures. Many of ArthroCare's products are based on its patented Coblation technology, which uses low-temperature radiofrequency energy to gently and precisely dissolve rather than burn soft tissue -- minimizing damage to healthy tissue. Used in more than four million surgeries worldwide, Coblation-based devices have been developed and marketed for sports medicine; spine/neurologic; ear, nose and throat (ENT); cosmetic; urologic and gynecologic procedures. ArthroCare also has added a number of novel technologies to its portfolio, including Opus Medical sports medicine and Parallax spine products, to complement Coblation within key indications.


Except for historical information, this press release includes forward-looking statements. These statements include, but are not limited to, the company's stated business outlook for fiscal 2005 and 2006, continued strength of the company's fundamental position, the strength of the company's technology, the company's belief that strategic moves will enhance achievement of the company's long term potential, the potential and expected rate of growth of new businesses, continued success of product diversification efforts, and other statements that involve risks and uncertainties. These risks and uncertainties include, but are not limited to the uncertainty of success of the company's non-arthroscopic products, competitive risk, uncertainty of the success of strategic business alliances, uncertainty over reimbursement, need for governmental clearances or approvals before selling products, the uncertainty of protecting the company's patent position, and any changes in financial results from completion of year-end audit activities. These and other risks and uncertainties are detailed from time to time in the company's Securities and Exchange Commission filings, including ArthroCare's Form 10-Q for the quarter ended March 31, 2005 and Form 10-K for the year ended Dec. 31, 2004. Forward-looking statements are indicated by words or phrases such as "anticipates," "estimates," "projects," "believes," "intends," "expects," and similar words and phrases. Actual results may differ materially from management expectations.


MediaLine Communications for ArthroCare Corp.
Paul Williams, 310-937-2009
[email protected]
For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

Contact us

RxPG Online



    Full Text RSS

© All rights reserved by RxPG Medical Solutions Private Limited (India)